Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation : prognostic implications. / Landes, Uri; Hochstadt, Aviram; Manevich, Lisa; Webb, John G.; Sathananthan, Janarthanan; Sievert, Horst; Piayda, Kerstin; Leon, Martin B.; Nazif, Tamim M.; Blusztein, David; Hildick-Smith, David; Pavitt, Chris; Thiele, Holger; Abdel-Wahab, Mohamed; Van Mieghem, Nicolas M.; Adrichem, Rik; Sondergaard, Lars; De Backer, Ole; Makkar, Raj R.; Koren, Ofir; Pilgrim, Thomas; Okuno, Taishi; Kornowski, Ran; Codner, Pablo; Finkelstein, Ariel; Loewenstein, Itamar; Barbash, Israel; Sharon, Amir; De Marco, Federico; Montorfano, Matteo; Buzzatti, Nicola; Latib, Azeem; Scotti, Andrea; Kim, Won Keun; Hamm, Christian; Franco, Luis Nombela; Mangieri, Antonio; Schoels, Wolfgang H.; Barbanti, Marco; Bunc, Matjaz; Akodad, Myriama; Rubinshtein, Ronen; Danenberg, Haim.

I: European Heart Journal, Bind 44, Nr. 15, 2023, s. 1331-1339.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Landes, U, Hochstadt, A, Manevich, L, Webb, JG, Sathananthan, J, Sievert, H, Piayda, K, Leon, MB, Nazif, TM, Blusztein, D, Hildick-Smith, D, Pavitt, C, Thiele, H, Abdel-Wahab, M, Van Mieghem, NM, Adrichem, R, Sondergaard, L, De Backer, O, Makkar, RR, Koren, O, Pilgrim, T, Okuno, T, Kornowski, R, Codner, P, Finkelstein, A, Loewenstein, I, Barbash, I, Sharon, A, De Marco, F, Montorfano, M, Buzzatti, N, Latib, A, Scotti, A, Kim, WK, Hamm, C, Franco, LN, Mangieri, A, Schoels, WH, Barbanti, M, Bunc, M, Akodad, M, Rubinshtein, R & Danenberg, H 2023, 'Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications', European Heart Journal, bind 44, nr. 15, s. 1331-1339. https://doi.org/10.1093/eurheartj/ehad146

APA

Landes, U., Hochstadt, A., Manevich, L., Webb, J. G., Sathananthan, J., Sievert, H., Piayda, K., Leon, M. B., Nazif, T. M., Blusztein, D., Hildick-Smith, D., Pavitt, C., Thiele, H., Abdel-Wahab, M., Van Mieghem, N. M., Adrichem, R., Sondergaard, L., De Backer, O., Makkar, R. R., ... Danenberg, H. (2023). Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications. European Heart Journal, 44(15), 1331-1339. https://doi.org/10.1093/eurheartj/ehad146

Vancouver

Landes U, Hochstadt A, Manevich L, Webb JG, Sathananthan J, Sievert H o.a. Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications. European Heart Journal. 2023;44(15):1331-1339. https://doi.org/10.1093/eurheartj/ehad146

Author

Landes, Uri ; Hochstadt, Aviram ; Manevich, Lisa ; Webb, John G. ; Sathananthan, Janarthanan ; Sievert, Horst ; Piayda, Kerstin ; Leon, Martin B. ; Nazif, Tamim M. ; Blusztein, David ; Hildick-Smith, David ; Pavitt, Chris ; Thiele, Holger ; Abdel-Wahab, Mohamed ; Van Mieghem, Nicolas M. ; Adrichem, Rik ; Sondergaard, Lars ; De Backer, Ole ; Makkar, Raj R. ; Koren, Ofir ; Pilgrim, Thomas ; Okuno, Taishi ; Kornowski, Ran ; Codner, Pablo ; Finkelstein, Ariel ; Loewenstein, Itamar ; Barbash, Israel ; Sharon, Amir ; De Marco, Federico ; Montorfano, Matteo ; Buzzatti, Nicola ; Latib, Azeem ; Scotti, Andrea ; Kim, Won Keun ; Hamm, Christian ; Franco, Luis Nombela ; Mangieri, Antonio ; Schoels, Wolfgang H. ; Barbanti, Marco ; Bunc, Matjaz ; Akodad, Myriama ; Rubinshtein, Ronen ; Danenberg, Haim. / Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation : prognostic implications. I: European Heart Journal. 2023 ; Bind 44, Nr. 15. s. 1331-1339.

Bibtex

@article{b75457eaec4e4be5958feed67dc7821a,
title = "Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications",
abstract = "Aims Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated. Methods A registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 and results centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007]. Conclusion This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.",
keywords = "Paravalvular regurgitation (PVR), Plug, Redo-TAVI, TAVI, Valvuloplasty",
author = "Uri Landes and Aviram Hochstadt and Lisa Manevich and Webb, {John G.} and Janarthanan Sathananthan and Horst Sievert and Kerstin Piayda and Leon, {Martin B.} and Nazif, {Tamim M.} and David Blusztein and David Hildick-Smith and Chris Pavitt and Holger Thiele and Mohamed Abdel-Wahab and {Van Mieghem}, {Nicolas M.} and Rik Adrichem and Lars Sondergaard and {De Backer}, Ole and Makkar, {Raj R.} and Ofir Koren and Thomas Pilgrim and Taishi Okuno and Ran Kornowski and Pablo Codner and Ariel Finkelstein and Itamar Loewenstein and Israel Barbash and Amir Sharon and {De Marco}, Federico and Matteo Montorfano and Nicola Buzzatti and Azeem Latib and Andrea Scotti and Kim, {Won Keun} and Christian Hamm and Franco, {Luis Nombela} and Antonio Mangieri and Schoels, {Wolfgang H.} and Marco Barbanti and Matjaz Bunc and Myriama Akodad and Ronen Rubinshtein and Haim Danenberg",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",
year = "2023",
doi = "10.1093/eurheartj/ehad146",
language = "English",
volume = "44",
pages = "1331--1339",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "15",

}

RIS

TY - JOUR

T1 - Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation

T2 - prognostic implications

AU - Landes, Uri

AU - Hochstadt, Aviram

AU - Manevich, Lisa

AU - Webb, John G.

AU - Sathananthan, Janarthanan

AU - Sievert, Horst

AU - Piayda, Kerstin

AU - Leon, Martin B.

AU - Nazif, Tamim M.

AU - Blusztein, David

AU - Hildick-Smith, David

AU - Pavitt, Chris

AU - Thiele, Holger

AU - Abdel-Wahab, Mohamed

AU - Van Mieghem, Nicolas M.

AU - Adrichem, Rik

AU - Sondergaard, Lars

AU - De Backer, Ole

AU - Makkar, Raj R.

AU - Koren, Ofir

AU - Pilgrim, Thomas

AU - Okuno, Taishi

AU - Kornowski, Ran

AU - Codner, Pablo

AU - Finkelstein, Ariel

AU - Loewenstein, Itamar

AU - Barbash, Israel

AU - Sharon, Amir

AU - De Marco, Federico

AU - Montorfano, Matteo

AU - Buzzatti, Nicola

AU - Latib, Azeem

AU - Scotti, Andrea

AU - Kim, Won Keun

AU - Hamm, Christian

AU - Franco, Luis Nombela

AU - Mangieri, Antonio

AU - Schoels, Wolfgang H.

AU - Barbanti, Marco

AU - Bunc, Matjaz

AU - Akodad, Myriama

AU - Rubinshtein, Ronen

AU - Danenberg, Haim

N1 - Publisher Copyright: © The Author(s) 2023.

PY - 2023

Y1 - 2023

N2 - Aims Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated. Methods A registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 and results centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007]. Conclusion This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.

AB - Aims Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated. Methods A registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 and results centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007]. Conclusion This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.

KW - Paravalvular regurgitation (PVR)

KW - Plug

KW - Redo-TAVI

KW - TAVI

KW - Valvuloplasty

U2 - 10.1093/eurheartj/ehad146

DO - 10.1093/eurheartj/ehad146

M3 - Journal article

C2 - 36883599

AN - SCOPUS:85152633036

VL - 44

SP - 1331

EP - 1339

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 15

ER -

ID: 366768051